Stellar Biotechnologies announces new hires
Port Hueneme immunotherapy developer Stellar Biotechnologies announced the expansion of its operations team, including new hires Liliana Marghitoiu, Luis Gonzalez Agraz and Kalam Azad. Marghitoiu will head up the company’s quality control department for protein processing and manufacturing. Azad will join Stellar’s senior aquaculture team, working with the giant keyhole limpets from which the company Read More →
Stellar Biotechnologies gets immunotherapy manufacturing contract
Port Hueneme immunotherapy company Stellar Biotechnologies announced an exclusive multi-year supply agreement with Taiwanese manufacturer Amaran Biotechnology. The agreement coincides with late-stage clinical studies for an immunotherapy called Adagloxad Simolenin, which treats cancers including metastatic breast cancer. The two companies will also develop the manufacturing process for Stellar’s Keyhole Limpet Hemocyanin conjugated vaccine, made from Read More →
Stellar Biotechnologies offerings raise $6.75 million
Stellar Biotechnologies, a Port Hueneme-based company which makes medicines from the blood of animals found only off the coast of California, closed two private offerings July 6. Stellar closed one offering of 1.7 million common shares sold to institutional investors for $4 per share. In a separate concurrent offering, the company also sold 1.3 million Read More →
Stellar Biotechnologies uses limpets to develop medicine
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Stellar Biotechnologies forming Paris-based company in joint venture
Stellar Biotechnologies will form a Paris-based company in a joint venture with Neovacs. The companies announced the partnership May 11. Neovacs, which is based in Paris, will own 70 percent of the new company, called Neostell. Stellar Biotechnologies will own 30 percent. Based in Port Hueneme, Stellar Biotechnologies makes a protein for immunotherapy treatments using Read More →
Stellar Biotechnologies revenues nearly doubled in first quarter
Stellar Biotechnologies revenues nearly doubled but so did the company’s losses during the first quarter, the Port Hueneme biotech company reported May 9. Stellar Biotechnologies makes a protein for immunotherapy treatments using a unique sea snail only found off the coastal shores of a small part of California. The company’s revenues increased from $187,627 during Read More →
Stellar Biotechnologies applies for delisting from TSX Venture Exchange
Port Hueneme-based Stellar Biotechnologies has applied for a voluntary delisting from Canada’s TSX Venture Exchange. Stellar makes a protein for immunotherapy treatments using a unique sea snail only found off the coastal shores of a small part of California. Common shares of Stellar Biotechnologies stock started trading on the Nasdaq stock exchange Nov. 5. The Read More →
